Results 161 to 170 of about 98,145 (299)

Re‐entry of donors deferred for false‐reactive screening tests in Canada: 10 years post implementation

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Canadian Blood Services implemented a re‐entry programme in 2014. Donors deferred because of false‐reactive or indeterminate screening tests can provide a specimen for re‐entry testing 6 months after their initial test, and resume donating if they test negative for all infectious markers.
Chinchin Wang, Steven J. Drews, Mark Bigham, Mindy Goldman, Sheila F. O'Brien   +4 more
wiley   +1 more source

Immunomodulatory Efficacy-Mediated Anti-HCV and Anti-HBV Potential of Kefir Grains; Unveiling the In Vitro Antibacterial, Antifungal, and Wound Healing Activities. [PDF]

Molecules, 2022
Ellatif SA, Abdel Razik ES, Abu-Serie MM, Mahfouz A, Shater AF, Saleh FM, Hassan MM, Alsanie WF, Altalhi A, Daigham GE, Mahfouz AY.   +10 more
europepmc   +1 more source

Atrial fibrosis in atrial fibrillation: Mechanisms, mapping techniques and clinical applications

The Journal of Physiology, EarlyView.
Abstract figure legend Summary of key aspects of atrial fibrosis in atrial fibrillation, highlighting atrial fibrosis as a hallmark of atrial fibrillation (AF). (1) Different types of fibrosis (blue), illustrating reparative and reactive fibrosis; (2) fibrosis detection techniques (green), illustrating late gadolinium enhancement cardiac magnetic ...
Caterina Vidal Horrach, Laura Bevis, Cynthia Nwanna, Alexander M Zolotarev, Mahmoud Ehnesh, Semhar Biniam Misghina, Sayed Al‐Aidarous, Shohreh Honarbakhsh, Caroline H. Roney   +8 more
wiley   +1 more source

Discovery of Novel 3-Hydroxyquinazoline-2,4(1H,3H)-Dione Derivatives: A Series of Metal Ion Chelators with Potent Anti-HCV Activities. [PDF]

Int J Mol Sci, 2022
Cao Y, Aimaiti A, Zhu Z, Zhou L, Ye D.
europepmc   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

HBV and HCV Burden in a Greek Hospital Population (2018-2024): Trends and Correlates of HBsAg and Anti-HCV Positivity. [PDF]

Pathogens
Georgiadis N, Seitopoulou C, Kimouli M, Sergentanis TN, Beloukas A, Tzanakaki G.   +5 more
europepmc   +1 more source

Anti-HCV-Antikörper [PDF]

, 2019
openaire   +1 more source

Hepatocyte growth factor/c‐Met signaling axis in human diseases: Mechanistic insights and therapeutic potential

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Figure 1 visually summarizes the core biological functions and therapeutic potential of the HGF/c‐Met signaling axis. Abstract Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c‐Met (mesenchymal–epithelial transition factor).
Hongqin Sun, Hao Shu, Qian Zhang, Jishan Zheng, Yunyan Ma, Dengwang Chen, Jidong Zhang, Tao Song   +7 more
wiley   +1 more source

Recent Advances in Anti-HCV, Anti-HBV and Anti-Flavivirus Agents. [PDF]

Viruses
Zoidis G.
europepmc   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source